You are here
Zosano Pharma to Host Key Opinion Leader Meeting on New Treatments for Migraine and the Migraine Patients’ Perspective
Live webcast of the event available for analysts and investors
FREMONT, Calif., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq: ZSAN) (“Zosano” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing therapies that deliver rapid systemic absorption by leveraging its novel and proprietary technology, Adhesive Dermally-Applied Microneedle System (“ADAM™”), today announced that it will host a Key Opinion Leader (KOL) meeting focusing on new treatments for migraine and the migraine patients’ perspective on Wednesday, October 24th, in New York City.
The meeting will feature presentations by KOLs Stewart J. Tepper, M.D. (Dartmouth-Hitchcock Medical Center) and Lawrence C. Newman, M.D. (NYU Langone) who will discuss updates on newly emerging treatments for the prevention of migraine, including CGRP antibodies, neurostimulation devices and new acute drug treatment products. In addition, the migraine patients’ perspective will be presented and discussed to provide context. Both KOLs will be available to answer questions at the conclusion of the event.
Members of Zosano’s management team will provide an overview of the clinical development of ADAM Zolmitriptan (M207). In February 2017, the Company announced statistically significant results from the ZOTRIP pivotal study, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at two hours. In November 2017, the Company announced the initiation of its long-term safety study evaluating M207 and expects to file a New Drug Application with the FDA for M207 in the fourth quarter of 2019.
Stewart J. Tepper, M.D. is professor of neurology at the Geisel School of Medicine at Dartmouth in Hanover, New Hampshire, and the director of the Dartmouth Headache Center in the Department of Neurology of Dartmouth-Hitchcock Medical Center in Lebanon, New Hampshire. He currently serves on the board of directors of the American Headache Society. In addition, Dr. Tepper has served as the co-director of the Scottsdale Headache Symposium course of the American Headache Society since 2008. He is also the editor-in-chief of the journal Headache Currents and associate editor for the journal Headache. Dr. Tepper has published more than 375 peer-reviewed manuscripts, editorials, and books on headache medicine. Dr. Tepper received his undergraduate degree in the study of the nervous system/psychobiology from Yale College in New Haven, Connecticut, and attended Cornell University Medical College in New York City. He completed his neurology residency at Harvard and has been board certified in headache medicine since 2006.
Lawrence C. Newman, M.D., is a clinical professor of neurology at the NYU Langone School of Medicine and the director of the division of headache at NYU Langone Medical Center. Prior to joining NYU, Dr. Newman was the director of the Headache Institute at Mount Sinai Roosevelt Hospital Center in New York City from 1998 until 2016. Dr. Newman completed his neurology residency and chief residency at the Albert Einstein College of Medicine in the Bronx, New York. He did his fellowship in headache medicine at the Montefiore Headache Center in the Bronx. He is a fellow of the American Academy of Neurology and the American Headache Society. He is also the immediate past president of the American Headache Society.
This event is intended for institutional investors, sell-side analysts, investment bankers and business development professionals only. Please RSVP in advance if you plan to attend, as space is limited. For those who are unable to attend in person, a live webcast and replay will be accessible via the link here. If you would like to ask a question during the live Q&A, please submit your request via the email.
M207 is Zosano’s proprietary formulation of zolmitriptan delivered utilizing its proprietary ADAM technology. Zosano's ADAM technology consists of titanium microprojections (microneedles) coated with drug, and in the case of M207, its formulation of zolmitriptan. The drug-coated microneedles penetrate into the epidermis and dermis, where the drug is dissolved and enters into the bloodstream. In February 2017, the Company announced statistically significant results from the ZOTRIP pivotal study, which demonstrated that the 3.8mg dose of M207 met both co-primary endpoints, achieving pain freedom and most bothersome symptom freedom at 2 hours. In November 2017, the Company announced the initiation of its long-term safety study evaluating M207 and expects to file a New Drug Application for M207 in the fourth quarter of 2019.
This press release contains forward-looking statements regarding the timing of expected clinical development milestones and other future events and expectations. Readers are urged to consider statements that include the words "may," "will," "would," "could," "should," "might," "believes," "estimates," "projects," "potential," "expects," "plans," "anticipates," "intends," "continues," "forecast," "designed," "goal," "unaudited," "approximately" or the negative of those words or other comparable words to be uncertain and forward-looking. These statements are subject to risks and uncertainties that are difficult to predict and actual outcomes may differ materially. These include risks and uncertainties, without limitation, associated with the process of discovering, developing and commercializing products that are safe and effective for use as human therapeutics, risks inherent in the effort to build a business around such products and other risks and uncertainties described under the heading "Risk Factors" in the Company's most recent annual report on Form 10-K. Although we believe that the expectations reflected in these forward-looking statements are reasonable, we cannot in any way guarantee that the future results, level of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. All forward-looking statements are based on information currently available to Zosano and Zosano assumes no obligation to update any such forward-looking statements.
Chief Executive Officer and Chairman of the Board
LifeSci Public Relations